Brands
5paisa Capital appoints Gaurav Seth as CEO
MUMBAI: 5paisa Capital has announced the appointment of Gaurav Seth as its CEO, effective immediately. With over two decades of experience in financial services and technology, Gaurav has a proven track record across the US, India, and southeast Asia. Prior to joining 5paisa, he served as chief product officer at Syfe, where he established it as a leading digital wealth player in southeast Asia. He also played a key role in propelling Paytm Money to prominence in India and led the digital transformation of Morgan Stanley’s wealth management division in New York.
Gaurav is an alumnus of the Indian School of Business, Hyderabad, and holds a bachelor of engineering from Thapar Institute of Engineering and Technology, Patiala.
5paise co-Promoter R. Venkataraman stated, “Seth’s experience in tech-driven innovations will enhance our digital transformation priorities at 5paisa Capital. We anticipate significant growth and innovation under his leadership.”
In response, Gaurav expressed, “5paisa Capital was the original disruptor in the Indian broking industry, democratizing equity investing for millions. I am excited to contribute to this legacy and spearhead the next phase of growth.”
5paisa.com stands as one of India’s largest discount brokers, boasting over 4.62 million customers and a reported net profit of Rs 219 million in Q2 FY25, with revenues reaching Rs 1008 million. The platform is widely used, with over 20.6 million users and a 4.3 rating on Google Play.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
